Oryzon Genomics announced on January 6th the appointment of Dr. Michael T. Ropacki as Vice President of Clinical and Product Development during the presentation made within the 2nd Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology at the Marines' Memorial Club in San Francisco (USA). Dr. Ropacki is the first Oryzon senior leadership team member to be based permanently in the US since the company was listed on the Spanish Market and is a key element for Oryzon's new stage of growth and a milestone for company. Dr. Ropacki has been the President of Strategic Global Research & Development (SGR&D) in San Francisco since January 2017.